CagriSema is a new medication in development from Novo Nordisk — the same company that makes Ozempic. It combines two drugs into one injection.
Quick Comparison
| Ozempic | CagriSema | |
|---|---|---|
| Active drug | Semaglutide | Semaglutide + Cagrilintide |
| Drug class | GLP-1 agonist | GLP-1 + Amylin agonist |
| FDA approval | Type 2 diabetes (approved) | In clinical trials |
| Dosing | Once weekly | Once weekly (in trials) |
| Status | Available now | Not yet FDA-approved |
What Is CagriSema?
CagriSema combines two drugs:
- Semaglutide — the same drug in Ozempic and Wegovy (GLP-1 agonist)
- Cagrilintide — a new amylin receptor agonist that also signals fullness
Think of it as adding a second fullness signal on top of the GLP-1 signal.
Weight Loss Results
From clinical trials:
- Ozempic: ~10-15% body weight loss
- CagriSema (in trials): ~20-25% body weight loss
CagriSema has shown stronger weight loss results in trials than semaglutide alone. The added cagrilintide appears to boost the effect.
Why This Matters
CagriSema could be the next step for people who:
- Tried semaglutide and didn't lose enough weight
- Want a single injection instead of multiple medications
- Are looking for results closer to what tirzepatide (Mounjaro/Zepbound) offers
Side Effects
Based on trial data, CagriSema causes similar side effects to other GLP-1 medications:
- Nausea
- Decreased appetite
- Vomiting
- Diarrhea or constipation
Because it hits two pathways, some people may experience stronger side effects. More data is needed.
Availability
CagriSema is not yet FDA-approved. Novo Nordisk has been running Phase 3 trials. If approved, it would likely launch as a weight loss medication (similar to Wegovy) and possibly for diabetes (similar to Ozempic).
Cost
No pricing is available yet. It will likely be priced similarly to other Novo Nordisk GLP-1 medications (~$1,000-1,350/month).
Who Might Benefit from CagriSema?
- People who plateau on semaglutide alone
- People who want stronger weight loss without switching to tirzepatide
- People who prefer to stay with Novo Nordisk products
Bottom Line
CagriSema combines semaglutide with a new drug to produce stronger weight loss. It's not available yet, but it could be an important option when it launches.
If you're on Ozempic now and it's working, there's no reason to wait. If you're not getting the results you want, talk to your doctor about your options — including switching to tirzepatide (Mounjaro/Zepbound) while CagriSema is still in trials.
Work with your healthcare provider to determine which medication is right for you. Individual results and experiences vary.
